PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
53.82%
Cash & equivalents growing 53.82% while GNPX's declined -84.82%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
53.82%
Below half of GNPX's -84.82%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
54.98%
Below half of GNPX's -69.83%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-8.67%
Below half GNPX's 6.69%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.00%
Below half of GNPX's 24.58%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
53.46%
≥ 1.5x GNPX's 10.07%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
21.21%
Less than half of GNPX's 82.65%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-57.02%
50-75% of GNPX's -100.00%. Bruce Berkowitz notes a more controlled liability line.
37.02%
50-75% of GNPX's 71.88%. Bruce Berkowitz notes the firm keeps current liabilities growth relatively low.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
37.02%
50-75% of GNPX's 71.88%. Bruce Berkowitz notes a lower yoy liability increase.
37.77%
Above 1.5x GNPX's 0.29%. Michael Burry suspects heavy new equity expansion or dilution.
-3.87%
Similar yoy to GNPX's -3.98%. Walter Schloss sees parallel earnings retention vs. competitor.
-5.55%
Higher AOCI Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
59.08%
Below half GNPX's -109.78%. Michael Burry sees potential underperformance in building shareholder capital.
53.46%
≥ 1.5x GNPX's 10.07%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-53.82%
Less than half of GNPX's 557.57%. David Dodd sees better deleveraging or stronger cash buildup than competitor.